<DOC>
	<DOCNO>NCT01336530</DOCNO>
	<brief_summary>This randomise , double-blind , placebo-controlled , therapeutic confirmatory multicentre trial 4 parallel treatment group . The design adaptive group-sequential two interim analysis , possible sample size re-estimation first second interim analysis drop-the-loser approach . The study design primarily choose show superior efficacy Tepilta® compare single component placebo . Evaluation safety secondary objective .</brief_summary>
	<brief_title>Tepilta® Versus Oxetacaine , Antacids Placebo</brief_title>
	<detailed_description>Tepilta® Suspension indicate treatment pain upper digestive system induced radiation therapy , particular radiation-induced oesophagitis .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<mesh_term>Antacids</mesh_term>
	<mesh_term>Magnesium Hydroxide</mesh_term>
	<mesh_term>Anti-Ulcer Agents</mesh_term>
	<mesh_term>Oxethazaine</mesh_term>
	<criteria>1 . Male female ≥ 18 year . 2 . Score = 0 NRS oesophageal pain . 3 . Radiotherapy ( RT ) combine radiochemotherapy ( RCT ) solid tumour head/neck/thorax region . A minimum length 5 cm oesophagus must include highdose radiation field . 4 . Duration RT 5 8 week . 5 . Single radiation dosage fractionate RT 1.8 2.0 Gy/day , intensitymodulated RT ( IMRT ) 1.5 2.3 Gy/day , 5 day week ( single frequency deviation allow presume intend duration RT remain 5 8 week ) . 6 . First radiation intend radiation area . 7 . Written informed consent . Randomisation criterion : 8 . Appearance oesophageal pain follow : Score ≥ 2 Numeric Rating Scale ( NRS ) pain main daily meal reach least . 9 . At least 20 Gy dose radiation therapy oesophageal area remain . 10 . Oesophageal symptom grade ≤ 2a accord adapted Common Terminology Criteria Adverse Events CTCAE . 1 . History allergic reaction study medication excipients ( i.e . aluminium magnesium hydroxide , oxetacaine , ingredient study medication ) . 2 . Pregnancy , breastfeed plan pregnancy study . 3 . Known hypermagnesaemia . 4 . Known hypophosphataemia . 5 . Clinically significant obstipation , judge investigator . 6 . Acute appendicitis . 7 . Total intend radiation dose lip anterior oral cavity &gt; 60 % total intended radiation dose swallow process ( pharynx , oesophagus ) . 8 . Hyperfractionated RT . 9 . Intended nasogastral tube . 10 . Primary tumour cranial base , brain , oral cavity , lip , nasopharynx , paranasal sinus . 11 . Known bone metastasis . 12 . Reflux oesophagitis 3 month prior study . 13 . Continuous systemic pain treatment begin RT . Systemic pain medication oesophagitis prior randomisation must take . 14 . Concomitant treatment tetracycline , cinolone derivative ( ciprofloxacin , ofloxacin , enoxacin , norfloxacin ) , chenodesoxycholic acid , sodium fluoride , local anaesthetic ( use study medication ) . 15 . Patients rely levothyroxine resection thyroid carcinoma hypothyroid patient rely levothyroxine due reason euthyroid . 16 . Artificial nutrition begin radiation . 17 . Drug ( licit illicit ) alcohol abuse would interfere patient 's proper completion study . 18 . Exposure investigational product within last 4 week , simultaneous exposure another investigational product . 19 . Lack ability willingness give inform consent . 20 . Anticipated nonavailability study visit / procedure . 21 . Lack ability willingness keep patient 's diary . 22 . Lack willingness personal study relate data collect , archive transmit accord protocol . 23 . Vulnerable subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Oesophageal pain</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Combined radio-chemotherapy</keyword>
	<keyword>Oesophageal symptom</keyword>
</DOC>